{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Orben F"],"funding":["Deutsche Forschungsgemeinschaft"],"pagination":["e151353"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9220834"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["7(10)"],"pubmed_abstract":["Systemic therapies for pancreatic ductal adenocarcinoma (PDAC) remain unsatisfactory. Clinical prognosis is particularly poor for tumor subtypes with activating aberrations in the MYC pathway, creating an urgent need for novel therapeutic targets. To unbiasedly find MYC-associated epigenetic dependencies, we conducted a drug screen in pancreatic cancer cell lines. Here, we found that protein arginine N-methyltransferase 5 (PRMT5) inhibitors triggered an MYC-associated dependency. In human and murine PDACs, a robust connection of MYC and PRMT5 was detected. By the use of gain- and loss-of-function models, we confirmed the increased efficacy of PRMT5 inhibitors in MYC-deregulated PDACs. Although inhibition of PRMT5 was inducing DNA damage and arresting PDAC cells in the G2/M phase of the cel"],"journal":["JCI insight"],"pubmed_title":["Epigenetic drug screening defines a PRMT5 inhibitor-sensitive pancreatic cancer subtype."],"pmcid":["PMC9220834"],"funding_grant_id":["see comments","SCHN 959/3-2,"],"pubmed_authors":["Boniolo F","Braun CJ","Wang C","Wirth M","Beyer G","Mahajan UM","Schmid RM","Schneider G","Schneider C","Kong B","Ollinger R","Rad R","Jakubowsky H","Mayerle J","Schlag C","Saur D","Orben F","Xue Y","Hassan Z","Schafer A","Lankes K","Schneeweis C","Murr J","Kuster B","Krauß L","Reichert M"],"additional_accession":[]},"is_claimable":false,"name":"Epigenetic drug screening defines a PRMT5 inhibitor-sensitive pancreatic cancer subtype.","description":"Systemic therapies for pancreatic ductal adenocarcinoma (PDAC) remain unsatisfactory. Clinical prognosis is particularly poor for tumor subtypes with activating aberrations in the MYC pathway, creating an urgent need for novel therapeutic targets. To unbiasedly find MYC-associated epigenetic dependencies, we conducted a drug screen in pancreatic cancer cell lines. Here, we found that protein arginine N-methyltransferase 5 (PRMT5) inhibitors triggered an MYC-associated dependency. In human and murine PDACs, a robust connection of MYC and PRMT5 was detected. By the use of gain- and loss-of-function models, we confirmed the increased efficacy of PRMT5 inhibitors in MYC-deregulated PDACs. Although inhibition of PRMT5 was inducing DNA damage and arresting PDAC cells in the G2/M phase of the cel","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 May","modification":"2026-05-28T06:25:07.124Z","creation":"2025-04-22T03:07:26.981Z"},"accession":"S-EPMC9220834","cross_references":{"pubmed":["35439169"],"doi":["10.1172/jci.insight.151353"]}}